Comment on: “Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(T)ide Analogues”: The Critical Need to Assess Serial Score Changes for Dynamic Risk Stratification

Documenti analoghi

• Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues
  di: Hongsheng Yu, et al.
  Pubblicazione: (2025)
• Response to the Letter Regarding “Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues”
  di: Hongsheng Yu, et al.
  Pubblicazione: (2026)
• Hepatitis B Surface Antigen Seroclearance Rate After Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B—A Systematic Review and Meta‐Analysis
  di: Soe Thiha Maung, et al.
  Pubblicazione: (2025)
• Polygenic Risk Scores in Chronic Hepatitis B–Related HCC: Promise Beyond Conventional Models?
  di: Talha Khan, et al.
  Pubblicazione: (2026)
• Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B
  di: Tyng‐Yuan Jang, et al.
  Pubblicazione: (2025)